Recently Featured

Biovac Secures $108M Financing for Vaccine Manufacturing Facility in South Africa

April 20, 2026
Biovac’s new vaccine factory in Cape Town, projected to produce up to 40 million vaccines annually, has successfully secured $108 million in financing from the European Investment Bank, the European Commission, and the International Finance Corporation. This significant investment underscores the growing emphasis on local vaccine production capabilities, particularly in regions that have historically relied…

Revolution Medicines’ buyout price soars after pancreatic cancer win

April 20, 2026
Revolution Medicines has seen its buyout valuation surge following the successful results of its Phase 3 clinical trial for a pancreatic cancer treatment. Initially rumored to be in the vicinity of $30 billion, the company’s market position has dramatically shifted with the recent positive data, which underscores the potential of its lead asset in a…

TRACERx MRD Results Showcase ppmSeq’s Ultra-Sensitive ctDNA Detection at AACR

April 20, 2026
At the recent AACR meeting, Ultima Genomics unveiled compelling findings regarding its ppmSeq technology, which demonstrates ultra-sensitive detection of circulating tumor DNA (ctDNA) relevant to minimal residual disease (MRD). This technology is pivotal for assessing treatment efficacy and predicting relapse in cancer patients, a critical need in oncology. The TRACERx study, one of the largest…

CVMP Grants Positive Opinion for Nobivac NXT HCPChFeLV Marketing Authorization

April 19, 2026
The Committee for Veterinary Medicinal Products (CVMP) has adopted a positive opinion for the marketing authorization of Nobivac NXT HCPChFeLV, aimed at the active immunization of cats against multiple infectious diseases. This decision, made during the CVMP meeting held from April 14 to 16, 2026, underscores the committee’s ongoing commitment to enhancing animal health through…

Ongoing Cases